Cite
Bernabeu I, Pico A, Venegas E, et al. Erratum to: Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 2016;19(4):460doi: 10.1007/s11102-016-0719-0.
Bernabeu, I., Pico, A., Venegas, E., Aller, J., Alvarez-Escolá, C., García-Arnés, J. A., Marazuela, M., Jonsson, P., Mir, N., Vargas, M. G. (2016). Erratum to: Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary, 19(4), 460. https://doi.org/10.1007/s11102-016-0719-0
Bernabeu, I, et al. "Erratum to: Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY." Pituitary vol. 19,4 (2016): 460. doi: https://doi.org/10.1007/s11102-016-0719-0
Bernabeu I, Pico A, Venegas E, Aller J, Alvarez-Escolá C, García-Arnés JA, Marazuela M, Jonsson P, Mir N, Vargas MG. Erratum to: Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 2016 Aug;19(4):460. doi: 10.1007/s11102-016-0719-0. PMID: 27147540.
Copy
Download .nbib